1+ mon, 4+ week ago (446+ words) On Tuesday, Pfizer Inc. (NYSE:PFE) announced a historic agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines. President Donald J. Trump announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price), the White House said in a statement. The White House stated that more than 100 million patients affected by diseases treated with Pfizer medicines are expected to benefit from President Trump's successful negotiation of lower prices. Also Read: Pfizer Faces Court Over Depo-Provera Brain Tumor Claims Eucrisa, a topical ointment for atopic dermatitis, will be available at an 80% discount for patients purchasing directly. Xeljanz, used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, will be offered at a 40% discount, while Zavzpret, a…...

3+ week, 5+ day ago (329+ words) Backed by Mastercard and PayPal, Pine Labs trims IPO size but targets a near $3B valuation in Mumbai debut Oops, something went wrong India's Fintech Giant Pine Labs Launches $439M IPO--Here's What Investors Need to Know This article first appeared on GuruFocus. Pine Labs is stepping into India's public markets with a bold move that could redefine the country's fintech playbook. The Mastercard (MA)- and PayPal (NASDAQ:PYPL)-backed digital payments company plans to raise as much as 39 billion rupees ($439 million) through an IPO in Mumbai, according to its latest filing. Shares will be offered between 210 and 221 rupees each, with anchor bids opening November 6 and public subscriptions running from November 7 to 11. At the top of that range, Pine Labs could fetch a valuation near 253.77 billion rupees, signaling strong investor appetite for India's fast-digitizing economy. The offering is split between a fresh…...

5+ mon, 1+ week ago (676+ words) Study: Over half incorrectly believe Medicare will cover long-term care costs, while six in 10 plan to rely on Medicaid As Americans live longer than ever " with the U.S. Census Bureau projecting the number of centenarians'to quadruple by 2054" the likelihood of needing LTC, and needing it for many years, is rising sharply. And many are not ready: 41% of Americans doubt they will live long enough to use long-term care insurance, even though nearly 70% of Americans turning 65'today will need LTC. Potential cuts to Medicaid could significantly impact LTC options for our aging population, as the program is the single largest source of funding for these services. Despite its critical role, 50% of Americans do not believe that cuts to Medicaid will affect their own LTC " a disconnect that highlights the urgent need to educate the public about the real financial risks associated with…...

7+ mon, 1+ week ago (547+ words) Gross Direct Premium Income (GDPI): INR 268.33 billion in FY25, growth of 8.3% compared to industry growth of 6.2%. Motor Segment GDP: INR 107.4 billion in FY25, growth of 11.5%. Health Segment GDP: INR 69.5 billion in FY25, growth of 12.6%. Commercial Lines Segment GDP: INR 69.95 billion in FY25, growth of 2.1%. Combined Ratio: 102.8% for FY25, improved from 103.3% in FY24. Investment Assets: INR 535.08 billion as of March 31, 2025. Investment Income: INR 42.5 billion in FY25, up from INR 36.1 billion in FY24. Profit Before Tax (PBT): INR 33.21 billion in FY25, growth of 30%. Profit After Tax (PAT): INR 25.08 billion in FY25, growth of 30.7%. Return on Average Equity: 19.1% in FY25, up from 17.2% in FY24. Solvency Ratio: 2.69 times as of March 31, 2025. Dividend: Proposed final dividend of INR 7 per share for FY25, total dividend of INR 12.5 per share. Warning! GuruFocus has detected 4 Warning Signs with THCH. Release Date: April 15, 2025 ICICI Lombard General Insurance Co Ltd (NSE:ICICIGI) achieved a gross direct premium income growth of 8.3% for FY2025, outperforming the…...

4+ mon, 2+ week ago (733+ words) Gross Direct Premium Income (GDPI): INR77.35 billion in Q1 FY26, a growth of 0.6% from INR76.88 billion in Q1 FY25. Commercial Lines Growth: 6.8% in Q1 FY26 compared to industry growth of 13%. Motor Segment GDPI: INR24.44 billion in Q1 FY26, a growth of 3.2% from INR23.69 billion in Q1 FY25. Health Segment GDPI: INR23.81 billion in Q1 FY26, a growth of 1.9% from INR23.37 billion in Q1 FY25. Combined Ratio: 102.9% for Q1 FY26 compared to 102.3% for Q1 FY25. Investment Income: INR12.88 billion in Q1 FY26, up from INR11.28 billion in Q1 FY25. Profit Before Tax: INR9.94 billion in Q1 FY26, a growth of 28.4% from INR7.74 billion in Q1 FY25. Profit After Tax: INR7.47 billion in Q1 FY26, a growth of 28.7% from INR5.8 billion in Q1 FY25. Return on Average Equity: 20.5% in Q1 FY26 compared to 19.1% in Q1 FY25. Solvency Ratio: 2.7 times as of June 30, 2025, compared to 2.69 times as of March 31, 2025. Warning! GuruFocus has detected 8 Warning Signs with STT. Release Date: July 15, 2025 ICICI Lombard General Insurance Co Ltd (NSE:ICICIGI) reported a profit after tax growth of 28.7% to INR7.47 billion in Q1 FY26 compared to INR5.8 billion in Q1 FY25. The company's investment income increased to INR12.88 billion…...

1+ mon, 2+ week ago (405+ words) For the first time, employers can compare what they paid to what they should have paid, identify hidden fees, and demand fair prices from health plans and providers. Boeing, Qualcomm, City and County of Denver Tout Transformational Impact of Proprietary Look at Newly Accessible Data The year-long project was made possible with support from strategic partners including Milliman, Embold Health, The Leapfrog Group, EY, and with funding and thought partnership from the Peterson Center on Healthcare. Together, the partners aggregated and analyzed claims, transparency, and quality data, overcoming major inconsistencies and barriers that have long stymied employers" ability to act. "This project has demonstrated the real potential of transparency data to transform the market," said Caroline Pearson,Executive Director at the Peterson Center on Healthcare."The only stakeholders who can meaningfully create downward pressure on prices right now are employers…...

2+ mon, 2+ week ago (541+ words) Why Centene is lagging behind its peers The Discounted Cash Flow (DCF) model estimates a company's true value by projecting its future cash flows and discounting them back to today's dollars. This approach helps investors understand what Centene is realistically worth at present based on the money it is expected to generate in the future. Based on this analysis, Centene's estimated intrinsic value comes in at $184.27 per share, a striking contrast to its recent trading price. This valuation implies the stock is trading at an 82.0% discount to its fair value, making it deeply undervalued by DCF standards. Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Centene. Our Discounted Cash Flow (DCF) analysis suggests Centene is undervalued by 82.0%. Track this in your watchlist or portfolio, or discover more…...

4+ mon, 1+ week ago (230+ words) FinThrive, Inc., a leading healthcare revenue cycle management software-as-a-service (SaaS) provider, today released a new infographic outlining the timeline and impact of key healthcare policy provisions included in the One Big Beautiful Bill Act (OBBBA). The visual resource highlights policy changes and implementation dates that affect patients, providers, payers, and healthcare systems'offering clear, concise insight into how the law's most significant reforms will unfold over the next severa Oops, something went wrong FinThrive Releases Visual Timeline of Healthcare Provisions in the One Big Beautiful Bill Act (OBBBA) PLANO, Texas, July 22, 2025 /PRNewswire/ -- FinThrive, Inc., a leading healthcare revenue cycle management software-as-a-service (SaaS) provider, today released a new infographic outlining the timeline and impact of key healthcare policy provisions included in the One Big Beautiful Bill Act (OBBBA). The visual resource highlights policy changes and implementation dates that affect patients, providers, payers,…...

8+ mon, 2+ week ago (479+ words) Commercial Lines Insurance Pricing Survey: Q4 2024NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- U.S. commercial insurance rates showed a continued upward trend with signs of moderation in the fourth quarter of 2024, according to the latest findings from WTW's Commercial Lines Insurance Pricing Survey (CLIPS). The survey compares premiums for policies underwritten during the fourth quarter of 2024 to those for the same coverage in the respective quarter of 2023, providing a year-over-year perspect Oops, something went wrong U.S. commercial insurance rates continue to rise, moderating to 5.6% increase Commercial Lines Insurance Pricing Survey: Q4 2024 NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- U.S. commercial insurance rates showed a continued upward trend with signs of moderation in the fourth quarter of 2024, according to the latest findings from WTW's Commercial Lines Insurance Pricing Survey (CLIPS). The survey compares premiums for policies underwritten during the fourth quarter of 2024 to those for the same coverage in the respective…...

3+ week, 1+ day ago (70+ words) Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over? Oops, something went wrong The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?...